Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Analysts

Pharvaris N.V. (NASDAQ:PHVS) has received an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $59.50.

PHVS has been the subject of a number of analyst reports. Citizens Jmp upped their price target on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a research report on Wednesday. Royal Bank Of Canada boosted their price objective on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Wednesday. Finally, Oppenheimer restated an “outperform” rating and set a $75.00 target price on shares of Pharvaris in a research note on Tuesday.

Insider Activity

In other news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director directly owned 315,167 shares of the company’s stock, valued at $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the sale, the insider owned 93,969 shares in the company, valued at $3,334,959.81. The trade was a 24.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 133,655 shares of company stock valued at $4,798,202. 11.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP purchased a new position in shares of Pharvaris in the second quarter valued at about $1,143,000. Amundi boosted its stake in shares of Pharvaris by 61.4% in the second quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after acquiring an additional 18,992 shares during the period. California State Teachers Retirement System grew its position in shares of Pharvaris by 3,210.1% during the second quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock worth $27,646,000 after purchasing an additional 775,337 shares in the last quarter. Moore Capital Management LP bought a new stake in Pharvaris during the 2nd quarter valued at approximately $1,522,000. Finally, Alyeska Investment Group L.P. grew its holdings in Pharvaris by 225.5% during the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after buying an additional 281,829 shares in the last quarter.

Key Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Analysts continued to support Pharvaris after positive Phase 3 data for extended-release deucrictibant in the CHAPTER-3 prophylaxis trial. The drug met its primary and secondary efficacy endpoints, strengthening the case for regulatory filings expected to begin in the first half of 2027.
• Positive Sentiment: RBC Capital reaffirmed its Buy/Outperform view and raised its price target to $62 from $52, citing the potential for deucrictibant XR to capture share in the hereditary angioedema market. RBC Capital rating
• Positive Sentiment: Citizens JMP increased its target to $79 from $75 and maintained a Market Outperform rating. HC Wainwright reiterated Buy with a $60 target, while Wedbush maintained Outperform. These actions reflect growing analyst confidence following Pharvaris’ Phase 3 progress.
• Positive Sentiment: Commentary highlighted Pharvaris’ potential to offer oral therapies for both on-demand treatment and prevention of hereditary angioedema attacks, which could improve its competitive positioning. Pharvaris HAE market opportunity
• Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition in the HAE market. Pharvaris is still a clinical-stage biotechnology company, and RBC continues to classify the stock as speculative.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest sentiment overhang, although it does not alter the company’s clinical results.

Pharvaris Price Performance

Shares of PHVS stock opened at $37.51 on Friday. Pharvaris has a 1 year low of $20.65 and a 1 year high of $43.25. The firm has a fifty day moving average price of $35.01 and a 200-day moving average price of $31.34. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -12.30 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities research analysts expect that Pharvaris will post -3.1 EPS for the current year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.